Announcement of The Consolidated Financial Report for The 4th Quarter of 2024
2025.2.25
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/02/25 | Time of announcement | 18:53:39 |
| Subject | Announcement of The Consolidated Financial Report for The 4th Quarter of 2024 | ||||
| Date of events | 2025/02/25 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2025/02/25 2.Date of the audit committee approved:2025/02/25 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2024/01/01~2024/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):5,893,847 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):3,416,171 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,393,856 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,885,687 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):1,519,354 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):1,449,622 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):5.83 11.Total assets end of the period (thousand NTD):10,862,766 12.Total liabilities end of the period (thousand NTD):3,351,826 13.Equity attributable to owners of parent end of the period (thousand NTD):6,750,448 14.Any other matters that need to be specified:None. |
||||